311 related articles for article (PubMed ID: 31419588)
1. Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines.
Da Silva CG; Camps MGM; Li TMWY; Chan AB; Ossendorp F; Cruz LJ
Biomaterials; 2019 Nov; 220():119417. PubMed ID: 31419588
[TBL] [Abstract][Full Text] [Related]
2. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.
Da Silva CG; Camps MGM; Li TMWY; Zerrillo L; Löwik CW; Ossendorp F; Cruz LJ
Theranostics; 2019; 9(22):6485-6500. PubMed ID: 31588231
[TBL] [Abstract][Full Text] [Related]
3. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
4. Employing ATP as a New Adjuvant Promotes the Induction of Robust Antitumor Cellular Immunity by a PLGA Nanoparticle Vaccine.
Zhang Q; Huang W; Yuan M; Li W; Hua L; Yang Z; Gao F; Li S; Ye C; Chen Y; He J; Sun W; Yang X; Bai H; Ma Y
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54399-54414. PubMed ID: 33215918
[TBL] [Abstract][Full Text] [Related]
5. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
[TBL] [Abstract][Full Text] [Related]
6. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.
Mottas I; Bekdemir A; Cereghetti A; Spagnuolo L; Yang YS; Müller M; Irvine DJ; Stellacci F; Bourquin C
Biomaterials; 2019 Jan; 190-191():111-120. PubMed ID: 30415018
[TBL] [Abstract][Full Text] [Related]
7. Rational Design of PLGA Nanoparticle Vaccine Delivery Systems To Improve Immune Responses.
Gu P; Wusiman A; Zhang Y; Liu Z; Bo R; Hu Y; Liu J; Wang D
Mol Pharm; 2019 Dec; 16(12):5000-5012. PubMed ID: 31621331
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors.
Liu C; Chu X; Yan M; Qi J; Liu H; Gao F; Gao R; Ma G; Ma Y
Int J Pharm; 2018 Dec; 553(1-2):327-337. PubMed ID: 30393151
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
10. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
Kim H; Griffith TS; Panyam J
J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
[TBL] [Abstract][Full Text] [Related]
11. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
13. Biomaterials as Local Niches for Immunomodulation.
Adu-Berchie K; Mooney DJ
Acc Chem Res; 2020 Sep; 53(9):1749-1760. PubMed ID: 32786230
[TBL] [Abstract][Full Text] [Related]
14. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.
Kong M; Tang J; Qiao Q; Wu T; Qi Y; Tan S; Gao X; Zhang Z
Theranostics; 2017; 7(13):3276-3292. PubMed ID: 28900509
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles.
Kim NW; Kim SY; Lee JE; Yin Y; Lee JH; Lim SY; Kim ES; Duong HTT; Kim HK; Kim S; Kim JE; Lee DS; Kim J; Lee MS; Lim YT; Jeong JH
ACS Nano; 2018 Oct; 12(10):9702-9713. PubMed ID: 30141896
[TBL] [Abstract][Full Text] [Related]
17. Engineering Strategies for Lymph Node Targeted Immune Activation.
Chen Y; De Koker S; De Geest BG
Acc Chem Res; 2020 Oct; 53(10):2055-2067. PubMed ID: 32910636
[TBL] [Abstract][Full Text] [Related]
18. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
19. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
20. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
